<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Celldex Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/celldex-therapeutics-inc</link>
<description>Latest news and press releases for Celldex Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 20:01:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/celldex-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835563e78dffbe2df0e9a5e.webp</url>
<title>Celldex Therapeutics Inc</title>
<link>https://6ix.com/company/celldex-therapeutics-inc</link>
</image>
<item>
<title>Celldex to Present at Upcoming Investor Conference</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-to-present-at-upcoming-investor-conference</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-to-present-at-upcoming-investor-conference</guid>
<pubDate>Mon, 13 Apr 2026 20:01:00 GMT</pubDate>
<description>HAMPTON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in a fireside chat at H.C. Wainwright’s 4th Annual Inflammatory Skin Disease Virtual Conference on Tuesday, April 14 at 3:30 pm ET. The webcast of the presentations will be available on the "Events & Presentations" page of the "Investors" section of the Celldex website. Replays will be available for 90 days following the event. About CelldexCelldex is pioneering new horizons i</description>
</item>
<item>
<title>Celldex Announces Proposed Public Offering of Common Stock</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-proposed-public-offering-of-common-stock-4</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-proposed-public-offering-of-common-stock-4</guid>
<pubDate>Wed, 01 Apr 2026 20:01:00 GMT</pubDate>
<description>HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced that it has commenced an underwritten public offering for the sale of shares of its common stock. In addition, Celldex expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the offering. All of the shares of common stock are being offered by the Company. The final terms of the offering</description>
</item>
<item>
<title>Celldex Announces Pricing of $300 Million Public Offering of Common Stock</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-pricing-of-dollar300-million-public-offering-of-common-stock-12</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-pricing-of-dollar300-million-public-offering-of-common-stock-12</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an</description>
</item>
<item>
<title>Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Patient Quality of Life at AAD 2026</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-from-phase-2-chronic-spontaneous-urticaria-and-phase-2-cold-urticaria-and-symptomatic-dermographism-studies-demonstrating-rapid-profound-and-durable-improvements-in-patient-quality-of-life-at-aad-2026</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-from-phase-2-chronic-spontaneous-urticaria-and-phase-2-cold-urticaria-and-symptomatic-dermographism-studies-demonstrating-rapid-profound-and-durable-improvements-in-patient-quality-of-life-at-aad-2026</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>- Improvements seen across all six DLQI Domains indicating broad, beneficial impact on quality of life -- Data further demonstrates first-in-class and</description>
</item>
<item>
<title>Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-demonstrating-barzolvolimab-retreatment-achieves-similar-profound-efficacy-to-first-exposure-in-patients-with-cold-urticaria-coldu-and-symptomatic-dermographism-sd-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at-aaaai-2026</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-demonstrating-barzolvolimab-retreatment-achieves-similar-profound-efficacy-to-first-exposure-in-patients-with-cold-urticaria-coldu-and-symptomatic-dermographism-sd-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at-aaaai-2026</guid>
<pubDate>Sun, 01 Mar 2026 14:45:00 GMT</pubDate>
<description>- Late breaking Poster Presentation at AAAAI -- Ability to retreat facilitates a real-world paradigm in which treatment for ColdU and SD may be intermittent with barzolvolimab - HAMPTON, N.J., March 01, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented new positive data from the Phase 2 ColdU and SD Open Label Extension (OLE), highlighting that retreatment with barzolvolimab leads to rapid improvement in urticaria control after symptom recurrence. Barzolvolimab is a humanized monoclonal a</description>
</item>
<item>
<title>Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Further Demonstrating First-in-Class and Best-in-Dis...</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-demonstrating-barzolvolimab-retreatment-achieves-similar-profound-efficacy-to-first-exposure-in-patients-with-cold-urticaria-coldu-and-symptomatic-dermographism-sd-further-demonstrating-first-in-class-and-best-in-dis</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-positive-data-demonstrating-barzolvolimab-retreatment-achieves-similar-profound-efficacy-to-first-exposure-in-patients-with-cold-urticaria-coldu-and-symptomatic-dermographism-sd-further-demonstrating-first-in-class-and-best-in-dis</guid>
<pubDate>Sun, 01 Mar 2026 05:00:00 GMT</pubDate>
<description>Celldex Presents Positive Data Demonstrating Barzolvolimab Retreatment Achieves Similar Profound Efficacy to First Exposure in Patients with Cold Urticaria</description>
</item>
<item>
<title>Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at AAAAI 2026</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urticaria-csu-and-phase-2-cold-urticaria-coldu-and-symptomatic-dermographism-sd-studies-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at-aaaai-2026</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urticaria-csu-and-phase-2-cold-urticaria-coldu-and-symptomatic-dermographism-sd-studies-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at-aaaai-2026</guid>
<pubDate>Fri, 27 Feb 2026 19:45:00 GMT</pubDate>
<description>- Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved quality of life and reduced disease impact for patients with ColdU/SD at Week 20 -HAMPTON, N.J., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) presented additional positive data from the completed Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticar</description>
</item>
<item>
<title>Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease Barzolvolimab Profile at ...</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urticaria-csu-and-phase-2-cold-urticaria-coldu-and-symptomatic-dermographism-sd-studies-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-from-phase-2-chronic-spontaneous-urticaria-csu-and-phase-2-cold-urticaria-coldu-and-symptomatic-dermographism-sd-studies-further-demonstrating-first-in-class-and-best-in-disease-barzolvolimab-profile-at</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism</description>
</item>
<item>
<title>Celldex Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-reports-fourth-quarter-and-year-end-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Wed, 25 Feb 2026 21:01:00 GMT</pubDate>
<description>Enrollment completed in both Phase 3 chronic spontaneous urticaria global registration studies (EMBARQ-CSU 1 and 2) six months ahead of guidance; Topline data expected in Q4 26; BLA submission planned for 2027Phase 3 cold urticaria and symptomatic dermographism study (EMBARQ-ColdU and -SD) actively accruing Enrollment completed in Phase 2 prurigo nodularis and atopic dermatitis studies with topline data expected in 2026 Phase 1 CDX-622 Proof of Mechanism study in asthma initiatedCompany prepares</description>
</item>
<item>
<title>Celldex Completes Enrollment in Global Phase 3 Studies (EMBARQ-CSU1 and EMBARQ-CSU2) of Barzolvolimab in Chronic Spontaneous Urticaria</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-completes-enrollment-in-global-phase-3-studies-embarq-csu1-and-embarq-csu2-of-barzolvolimab-in-chronic-spontaneous-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-completes-enrollment-in-global-phase-3-studies-embarq-csu1-and-embarq-csu2-of-barzolvolimab-in-chronic-spontaneous-urticaria</guid>
<pubDate>Wed, 25 Feb 2026 12:01:00 GMT</pubDate>
<description>Enrollment completed six months ahead of guidance, driven by significant unmet need for better treatments in CSUTopline data expected Q4 2026BLA submission planned for 2027 HAMPTON, N.J., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the completion of enrollment in the Company’s global Phase 3 program of barzolvolimab in chronic spontaneous urticaria (CSU), which consists of two Phase 3 trials—EMBARQ-CSU1 and EMBARQ-CSU2. 1,939 patients were enrolled—the largest program</description>
</item>
<item>
<title>Celldex Announces Multiple Upcoming Presentations at AAAAI 2026 Supporting Barzolvolimab’s First-in-Class and Best-in-Disease Profile</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-multiple-upcoming-presentations-at-aaaai-2026-supporting-barzolvolimabs-first-in-class-and-best-in-disease-profile</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-multiple-upcoming-presentations-at-aaaai-2026-supporting-barzolvolimabs-first-in-class-and-best-in-disease-profile</guid>
<pubDate>Mon, 23 Feb 2026 13:01:00 GMT</pubDate>
<description>HAMPTON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that multiple presentations from the Company’s Phase 2 clinical trials of barzolvolimab in chronic spontaneous urticaria (CSU) and cold urticaria (ColdU) and symptomatic dermographism (SD) have been accepted for presentation at the 2026 American Academy of Allergy, Asthma & Immunology's (AAAAI) Annual Meeting being held in Philadelphia, February 27 – March 2. New data from the Phase 2 ColdU and SD Open Label E</description>
</item>
<item>
<title>Celldex Initiates Global Registrational Phase 3 Program of Barzolvolimab in Cold Urticaria and Symptomatic Dermographism</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-initiates-global-registrational-phase-3-program-barzolvolimab-cold-urticaria</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-initiates-global-registrational-phase-3-program-barzolvolimab-cold-urticaria</guid>
<pubDate>Tue, 09 Dec 2025 05:00:00 GMT</pubDate>
<description>No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient lifeBarzolvolimab is the only drug in</description>
</item>
<item>
<title>Celldex Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-reports-third-quarter-2025-financial-results-and-provides-corporate-update</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-reports-third-quarter-2025-financial-results-and-provides-corporate-update</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid,</description>
</item>
<item>
<title>Celldex Announces Appointment of Teri Lawver as Chief Commercial Officer</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-appointment-teri-lawver-chief-commercial-officer-2025-11-10</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-appointment-teri-lawver-chief-commercial-officer-2025-11-10</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief</description>
</item>
<item>
<title>Celldex to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-present-upcoming-investor-conferences-2025-11-07</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-present-upcoming-investor-conferences-2025-11-07</guid>
<pubDate>Fri, 07 Nov 2025 05:00:00 GMT</pubDate>
<description>HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following</description>
</item>
<item>
<title>Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-results-barzolvolimab-phase-130000591</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-results-barzolvolimab-phase-130000591</guid>
<pubDate>Thu, 06 Nov 2025 13:00:00 GMT</pubDate>
<description>First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD)All primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period (20 weeks)Up to 78% of patients with ColdU and 58% of patients with SD obtained a partial or complete response at Week 20Well tolerated through 20 weeks of dosingPhase 3 study in ColdU and SD to initiate in Dece</description>
</item>
<item>
<title>Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patient...</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-results-barzolvolimab-phase-2-study-cold-urticaria-coldu-and</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-results-barzolvolimab-phase-2-study-cold-urticaria-coldu-and</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and</description>
</item>
<item>
<title>Celldex Presents Additional Positive Data Demonstrating Barzolvolimab’s Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-demonstrating-barzolvolimabs-ability-drive</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-additional-positive-data-demonstrating-barzolvolimabs-ability-drive</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating</description>
</item>
<item>
<title>Celldex Announces Initial Positive Results from Phase 1 Trial of CDX-622 Demonstrating Favorable Safety and PK Profile and Sustained Mast Cell Inhibition</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-initial-positive-results-phase-1-trial-cdx-622-demonstrating</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-announces-initial-positive-results-phase-1-trial-cdx-622-demonstrating</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)</description>
</item>
<item>
<title>Celldex Presents Data Demonstrating Barzolvolimab Improves Chronic Spontaneous Urticaria Independent of Baseline Immunoglobulin E levels in Phase 2 Study at EADV Congress 2025</title>
<link>https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-data-demonstrating-barzolvolimab-improves-chronic-spontaneous</link>
<guid isPermaLink="true">https://6ix.com/company/celldex-therapeutics-inc/news/celldex-presents-data-demonstrating-barzolvolimab-improves-chronic-spontaneous</guid>
<pubDate>Wed, 17 Sep 2025 04:00:00 GMT</pubDate>
<description>Rapid and sustained efficacy regardless of baseline IgE levels in patients with CSU HAMPTON, N.J., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX)</description>
</item>
</channel>
</rss>